BusinessOtonomy Announces FDA Acceptance of OTIPRIO® Supplemental New Drug Application Filing for Acute Otitis ExternaBy Nasdaq OMXJul 18, 2017, 11:30 AM UTC
BusinessOtonomy Initiates Patient Enrollment in Phase 2 Clinical Trial of OTO-104 as Protectant Against Cisplatin-Induced Hearing LossBy Nasdaq OMXJan 19, 2017, 12:30 PM UTC
BusinessOtonomy Announces Positive Top-Line Results from Phase 3 Clinical Trial of OTIPRIO® in Patients with Acute Otitis ExternaBy Nasdaq OMXJan 5, 2017, 12:01 PM UTC
BusinessOtonomy Announces Positive Top-Line Results from Phase 3 Clinical Trial of OTIPRIO® in Patients with Acute Otitis ExternaBy Nasdaq OMXJan 5, 2017, 12:01 PM UTC
